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Purpose: RAX2 encodes a homeobox-containing transcription
factor, in which four monoallelic pathogenic variants have been
described in autosomal dominant cone-dominated retinal disease.
Methods: Exome sequencing in a European cohort with inherited
retinal disease (IRD) (n= 2086) was combined with protein
structure modeling of RAX2 missense variants, bioinformatics
analysis of deletion breakpoints, haplotyping of RAX2 variant
c.335dup, and clinical assessment of biallelic RAX2-positive cases
and carrier family members.
Results: Biallelic RAX2 sequence and structural variants were
found in five unrelated European index cases, displaying nonsyn-
dromic autosomal recessive retinitis pigmentosa (ARRP) with an
age of onset ranging from childhood to the mid-40s (average mid-
30s). Protein structure modeling points to loss of function of the
novel recessive missense variants and to a dominant-negative effect
of the reported dominant RAX2 alleles. Structural variants were
fine-mapped to disentangle their underlying mechanisms. Haplo-
typing of c.335dup in two cases suggests a common ancestry.
Conclusion: This study supports a role for RAX2 as a novel disease
gene for recessive IRD, broadening the mutation spectrum from
sequence to structural variants and revealing a founder effect. The
identification of biallelic RAX2 pathogenic variants in five unrelated
families shows that RAX2 loss of function may be a nonnegligible
cause of IRD in unsolved ARRP cases.
Genetics in Medicine (2019) 21:1319–1329; https://doi.org/10.1038/s41436-
018-0345-5
Keywords: RAX2; homeobox-containing transcription factor;
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INTRODUCTION
The development of the vertebrate eye is a well-coordinated
multistep process regulated by the interplay of genetic networks
and interactions with the extracellular environment. During
early development of the vertebrate central nervous system, the
eye field forms centrally within the anterior neural plate,
containing all the progenitors of the neural-derived eye
structures.1 This field is defined by the area where the
expression domains of a set of eye field transcription factors
(TFs) overlap. TFs such as Pax6, Rax, Six3, and Lhx2 are
homeobox-containing proteins that constitute a regulatory
network to specify retinal progenitor cells, giving rise to eye
structures such as the neural retina and the retinal pigment
epithelium (RPE).2 In particular, members of the retinal
homeobox (Rax) gene family are among the earliest markers
of the eye field, playing a pivotal role during vertebrate eye
development. Loss of function of RAX1 orthologues in mice,3
medaka,4 zebrafish,5 and Xenopus6 results in an eyeless
phenotype due to failure of optic vesicle formation, indicating
the essential role of RAX1 genes in normal eye development. In
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contrast, RAX2 deficient chicken,7 Xenopus,8 and zebrafish9
models demonstrate that RAX2 is required for cell proliferation
and differentiation within the retina by regulating the spatial
expression of photoreceptor-specific genes in late retinogenesis.
In humans, the RAX paralogues appear to function in a
manner similar to that observed in other species, because
genetic defects in RAX have been associated with both
anophthalmia and microphthalmia,10 while pathogenic var-
iants in RAX211,12 cause autosomal dominantly inherited
retinal disease (IRD). RAX2 shares a nearly identical (93%)
homeodomain with RAX, although limited homology is
observed elsewhere. Its expression is mainly limited to the
outer and inner nuclear layers of the retina. RAX2 functions
as a transcriptional coactivator by synergistically increasing
the transactivation activity of the photoreceptor-specific TFs
through physical interaction with CRX.11
So far, only a handful of likely pathogenic RAX2 variants
(NM_032753) have been described. Wang et al. reported
three heterozygous sequence variants in single patients with
IRD, which they tentatively associated with central retinal
degeneration.11 The c.409G>C p.(Gly137Arg) and
c.417_422dup p.(Pro140_Gly141dup) variants were found
in two patients with cone–rod dystrophy (CRD). These
variants exhibit, respectively, a reduced and an increased
transactivation activity in vitro in the presence of CRX and
NRL, as well as a decreased interaction with CRX. The
c.260G>A p.(Arg87Gln) variant was found in a patient with
age-related macular degeneration (AMD), and linked to an
increased transactivation function in vitro. However,
because no segregation analysis was performed, the authors
only raised the possibility that RAX2 may be involved in
disease pathogenesis. Yang et al. identified one additional
heterozygous RAX2 variant, c.465_475del p.
(Ala156Argfs*131), in a family with autosomal dominant
cone or cone–rod dystrophy.12
Here, we report the identification of RAX2 as a novel
disease gene mutated in autosomal recessive retinitis pigmen-
tosa (ARRP), a rod–cone type of IRD, in five unrelated
families of Belgian, British, Italian, and Spanish origin.
MATERIALS AND METHODS
Patients and clinical evaluation
This study was approved by local ethics committees in
Belgium, Italy, Spain, and the United Kingdom (Supplemen-
tary File 1) and all participants gave informed consent.
Clinical assessment consisted of recording of a medical
history and of ophthalmic assessment, including fundus
examination, optical coherence tomography (OCT), visual
acuity measurement, Goldmann visual field testing, electro-
retinographic (ERG) testing following International Society
for Clinical Electrophysiology of Vision (ISCEV) standards,
and color vision assessment.
Exome sequencing
Genomic DNA was extracted from blood using the DNeasy
Blood & Tissue Kit (QIAGEN). For patients I, II, and V
exome enrichment was performed with the SureSelectXT
Human All Exon V5/V6 kit (Agilent), followed by paired-end
sequencing on a HiSeq 3000 system (Illumina). For patient
III, exome sequencing libraries were prepared using the
SureSelectQXT Clinical Research Exome V1 kit (Agilent) and
run on a NextSeq 500 system (Illumina). For patient IV,
clinical exome sequencing was performed using the commer-
cial TruSight One panel (Illumina) on a NextSeq 500 system
(Illumina). Read processing and variant calling were
performed using in-house developed pipelines.13–17 Copy-
number analysis was performed using the R package
ExomeDepth.18 Variants were confirmed and segregated by
Sanger sequencing using the BigDye Terminator v3.1 kit (Life
Technologies). Primer sequences are listed in Supplementary
Table 1.
Haplotype analysis of the recurrent Belgian variant
c.335dup
Runs of homozygosity (ROH) were determined from exome
sequencing data using the H3M2 algorithm.19 Additional
single-nucleotide polymorphisms (SNPs) were genotyped
using conventional polymerase chain reaction (PCR) and
Sanger sequencing (Supplementary Table 2). Microsatellite
primers were PCR amplified and products were analyzed on
an ABI Prism 3730xl Genetic Analyzer (Applied Biosystems).
Microsatellite genotyping calls were generated using Gene-
Mapper v5 software (Applied Biosystems).
Structural analysis of the RAX2 missense variants
Homology models for the RAX2 homeodomain were built
using automated homology modeling with automated
template searching in the Yasara software.20 Protein Data
Bank (PDB) codes of superposed structures are 3A01_A,
3A01_B, 1FLJ_A, 2H1K_A, 1IG7_A, 5Z2T_C. Models of
the RAX2/CRX/Ret-1 complex were built using the crystal
structure of aristaless and clawless homeodomains bound
to DNA (3A01) as template with a custom ungapped
sequence alignment. The template was first adapted by
mutating the DNA fragments to the Ret-1 sequence
GGGGCTTAATTGGCT and its complement. Models of
the RAX2/CRX/Ret-1 complex were further analyzed using
molecular dynamics in Yasara with 160-ns simulations.21
Effects of variants on stability and interactions were
predicted with FoldX, using the mutate residue command
with initial RepairPDB. Structure superpositions, Rama-
chandran plot, and images were created in University of
California–San Francisco (UCSF) Chimera.
Fine-mapping and bioinformatics study of the deletion
breakpoints
For the determination of deletion breakpoints, the High
Fidelity LA Taq DNA Polymerase (Takara) was used for long
range PCR. Amplicons of the proband were Sanger sequenced
and aligned to the reference genome (hg19) using the
University of California–Santa Cruz (UCSC) Genome Brow-
ser (http://genome.ucsc.edu/).
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For the RAX2 deletions identified in this study, a
bioinformatics analysis was performed to assess the under-
lying mechanism, as previously described.22 In particular, for
the breakpoint regions of the deletions we analyzed the degree
of microhomology (multiple sequence alignment, ClustalW),
the presence of repetitive elements (RepeatMasker track,
UCSC Genome Browser), the percentage of sequence identity
between repeat elements of the same class (BLAST), and the
presence of sequence motifs, based on 40 previously described
motifs (Fuzznuc).23
An integrated epigenomic profile of the RAX2 locus in adult
human retina was obtained by alignment of profiles obtained
by ATAC-seq and multiple ChIP-seq (H3K4me2, H3K27ac,
Crx, Otx2) experiments as described (www.biorxiv.org/
content/early/2018/09/08/412361).
RESULTS
Clinical findings
The families included in this study are of Belgian, British,
Italian, and Spanish origin and are part of a larger IRD cohort
(n= 2086, Supplementary Table 3) from the European
Retinal Disease Consortium (ERDC, https://www.erdc.info),
which aims to identify novel IRD genes and pathogenetic
mechanisms. All patients included were clinically diagnosed
with nonsyndromic retinitis pigmentosa (RP). Fundus and
OCT imaging revealed typical features of RP (Fig. 1) and
visual fields were restricted to about ten degrees in all patients.
Visual acuity ranged from normal (11/10) to hand move-
ments (1/10), with an average of 6/10. The age of onset varied
from childhood to mid-40s, with an average around mid-30s.
A possible consanguineous origin was reported in patients III
and IV. More detailed ophthalmic characteristics are provided
in Table 1 and Supplementary File 2. Fundus autofluorescence
images of all patients and ERG traces of patients II, III, and IV
are provided in Supplementary Figures 1 and 2 respectively.
Genetic findings
In five apparently unrelated families of Belgian (patients I–II),
Italian (patient III), Spanish (patient IV), and British (patients
V–VI) origin, biallelic novel RAX2 variants were identified (5/
2086, 0.24%; estimate of 1000 RP cases: 5/1000, 0.50%). A
summary of the molecular genetic findings can be found in
Fig. 2 and Table 2. An overview of the exome sequencing
variant filtering for each patient can be found in Supplemen-
tary File 3.
Exome sequencing in unrelated patients I and II revealed a
novel frameshift variant, c.335dup p.(Ala113Glyfs*178), in
homozygous state in exon 3 of RAX2. Except for one
heterozygous entry in the European population in the
Genome Aggregation Database (gnomAD, r2.0.1)
(0.00084%), this variant is absent from other public databases
(1000 Genomes Project, ExAC, dbSNP, HGMD) (Table 2).
Because of its location in the last exon of RAX2, this variant is
predicted to escape nonsense mediated decay (NMD), giving
rise to a putative read-through protein that is 107 amino acids
longer than the wild-type RAX2 protein. An overview of other
biallelic variants identified by exome sequencing in patients I
and II is given in Supplementary Table 4. Based on gene
function and variant effect, the homozygous RAX2 frameshift
variant appears to be the most plausible pathogenic variant in
relation to the retinal phenotype. The pathogenic RAX2
variant was confirmed by Sanger sequencing and segregation
was demonstrated in both parents (Fig. 2a, b). Fundus
autofluorescence images of the unaffected carrier mother of
patient II are provided in Supplementary Figure 3A and did
not reveal any sign of retinal impairment.
The analysis of variants identified by exome sequencing in
patient III did not yield any high-confidence pathogenic
variants in known or candidate IRD genes (Supplementary
Table 4). Hence, the presence of copy-number variants
(CNVs) was evaluated by analyzing the exome sequencing
coverage data. This revealed that the 5’ end of the RAX2 gene
was devoid of any reads, suggesting a homozygous deletion
(Fig. 2c). Two primer pairs that anneal outside the putative
deleted region were used to delineate the deletion breakpoints
(Supplementary Table 1). Sanger sequencing of the junction
products determined the breakpoint extremities at nucleotide
level (chr19:3,771,337-3,774,298). The deleted region of 2.9 kb
spans the first two RAX2 exons, one noncoding and one
coding, containing the start and subsequent 71 codons,
spanning most of the homeodomain. Segregation analysis was
performed in two unaffected siblings (II:3, II:4), who were
found to be heterozygous for the deletion. Both II:3 and II:4
underwent full ophthalmological assessment, including fun-
dus autofluorescence, OCT, and standard ERG. Neither of
them showed any sign of visual impairment (Supplementary
Figure 3B).
Exome sequencing revealed a novel homozygous missense
variant, c.145T>C p.(Ser49Pro), in the first coding exon of
RAX2 in patient IV. This variant, which is located in the
second largest homozygous region of this patient with
possible consanguineous origin, is absent from public
databases, is predicted to be pathogenic by different
computational algorithms (Table 2), and changes a highly
conserved serine residue located in the homeobox domain
(Fig. 3a). No additional (likely) pathogenic variants remained
after filtering. The variant was confirmed by Sanger sequen-
cing and found to be heterozygous in the unaffected sister
(III:2) (Fig. 2d).
Exome sequencing in patient V revealed potentially biallelic
variants in a total of five genes. An annotated list of these
variants is given in Supplementary Table 4. Of these, two
genes were identified as being known IRD genes, EYS and
RAX2. Segregation analysis of the EYS variants by Sanger
sequencing enabled these to be ruled out as causative for
disease. The variant in RAX2, c.155C>G p.(Pro52Arg),
appeared to be homozygous in patient V as well as in patient
VI. Subsequent CNV analysis of the exome sequencing data
demonstrated the presence of a heterozygous 7.1 kb deletion
spanning the entire RAX2 coding region extending to the 3’
end of the MRPL54 gene. Sanger sequencing of the PCR
junction products determined the breakpoint extremities at
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a Patient I b Patient II
c Patient III
d Patient IV
e Patient V
f Patient VI
g Patient I h Patient II
i Patient III j Patient IV
k Patient V l Patient VI
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Fig. 1 Fundus and optical coherence tomography (OCT) imaging in patients with RAX2-associated ARRP. a–f Fundus images and (g–l) OCT
images of patients I–VI (left eye) show features characteristic of retinitis pigmentosa as described in further detail in Table 1 and Supplementary File 2.
Notable features include variable degrees of pigmentation and a general preservation of foveal structure.
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nucleotide level (chr19:3,765,788-3,772,920). This led to the
conclusion that c.155C>G p.(Pro52Arg) is hemizygous.
Segregation analysis revealed heterozygosity of the missense
variant in one unaffected sibling (II:1) and absence in two
others (II:2, II:3) (Fig. 2e). The deletion was present in the
affected siblings, patient V and VI, while neither of the
unaffected siblings was a carrier of the deletion (Supplemen-
tary Figure 4). The novel missense variant p.(Pro52Arg)
changes a highly conserved proline residue located in the
homeobox domain (Fig. 3a), is absent from public databases,
and is predicted to be pathogenic by several computational
algorithms (Table 2).
Haplotype analysis of the recurrent Belgian variant
c.335dup
Because the same RAX2 variant, c.335dup p.(Ala113-
Glyfs*178), was identified in patients I and II, both of Belgian
origin, haplotype analysis was performed in these two patients
and four carriers (parents of the patients) to assess a common
ancestry. Genotyping of 24 SNPs and three microsatellites
distributed over a 1.3 Mb region showed a common disease
haplotype in the two RP patients and four unaffected carriers
of 447.3 kb with 6.2 kb and 13.7 kb border regions
(Fig. 2a’, b’) (Supplementary Figure 5). These findings are
consistent with a founder effect.
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I:1 I:2
II:1 II:2
III:1 III:2
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I:1 I:2 II:2
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Amplicon_A
Amplicon_B
Basic Gene Annotation Set from GENCODE Version 19
Your Sequence from Blat Search
3,770,000 3,771,000 3,772,000
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3,773,000 3,774,000
A392_mergebam_mrdup_sortidx.bam
3,775,000 3,776,000 3,777,000 3,778,000
hg19
RAX2
RAX2
MATK
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Fig. 2 Overview of identified RAX2 variants in five families with ARRP. a Pedigree of patient I, in which RAX2 variant c.335dup p.(Ala113Glyfs*178)
was found. Sanger sequencing traces indicate homozygosity in the patient (II:2) and heterozygosity in the unaffected parents (I:1, I:2). b Pedigree of patient
II, in which RAX2 variant c.335dup p.(Ala113Glyfs*178) was found. Sanger sequencing traces indicate homozygosity in the patient (III:8) and heterozygosity
in the unaffected parents (II:5, II:6). c Pedigree of patient III, in which homozygous RAX2 deletion g.3771337_3774298del was found. The absence of reads
mapped to the first two exons of RAX2 is visible on the exome sequencing coverage plot. The sequence of the junction polymerase chain reaction (PCR)
product spanning the 2.9 kb deletion is depicted below. d Pedigree of patient IV, in which RAX2 variant c.145T>C, p.(Ser49Pro) was found. Sanger
sequencing traces indicate homozygosity in the patient (III:4). e Pedigree of patient V and VI, in which RAX2 variants c.155C>G p.(Pro52Arg) and
g.3765788_3772920del were found. Sanger sequencing traces indicate hemizygosity in the patients (II:4, II:5). One of the three analyzed healthy siblings is
heterozygous for the missense variant (II:1), while the other two did not carry this variant (II:2, II:3). The sequence of the junction PCR product spanning the
7.1 kb deletion is depicted below. RAX2 variant nomenclature uses numbering with the A of the initiation codon ATG as +1 based on transcript
NM_032753. (a’, b’) Haplotype analysis of the c.335dup RAX2 variant. Genotyping of patients I, II, and both of their unaffected parents, using 24 intragenic
single-nucleotide polymorphisms (SNPs) and 3 microsatellites located in a region of 1.4Mb around the variant. The c.335dup RAX2 variant is indicated in
red. The blue bar represents the common disease haplotype, from SNP rs10424377 to SNP rs3760903. The maximal common region in the two families
spans 447.3 kb. mut mutant, wt wild type.
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Protein structure modeling of the RAX2 missense variants
Several homology models were built for the RAX2 home-
odomain, based on different homeodomain template struc-
tures. In all models, residues that are in proximity to DNA are
identical between RAX and RAX2, indicating that they bind
the same response elements. Residues Ser49 and Pro52 are
both part of the structurally conserved extended loop between
helix 1 and 2 of the homeodomain (Fig. 3b): Ser49 adapts a
backbone conformation that is not allowed for proline
(Supplementary Figure 6A) and the Pro52 proline ring inserts
into the hydrophobic core of the homeodomain three-helix
bundle (Supplementary Figure 6B). Pfam alignment of
homeodomains confirms that only a proline or hydrophobic
residue is allowed at position 52. Both p.(Ser49Pro) and p.
(Pro52Arg) variants are therefore expected to strongly affect
the folding and/or stability of the RAX2 protein, as supported
by FoldX stability computations in the homology models,
resulting in a loss of function.24
The aristaless and clawless homeodomains used to build the
model for the RAX2/CRX/Ret-1 complex bind at opposite
sides of a DNA fragment and directly interact with each other
via two important salt bridges.25 RAX2 and CRX interact with
each other in analogous fashion while bound to the
photoreceptor conserved element-1 (PCE-1/Ret-1) 11,26. In
this complex, the Arg87 residue located at the C-terminal end
of the RAX2 homeodomain helix 3 makes a stable salt bridge
with Glu70 of the CRX homeodomain (Fig. 3c). The
subsequent substitution of arginine by glutamine, p.
(Arg87Gln), found in a patient with dominant AMD,11
disrupts this salt bridge. In addition, homology modeling
suggests that the N-terminal extension of RAX2 encircles the
DNA strand and binds in the minor groove via a positively
charged binding motif that strongly resembles the motif in
clawless (Fig. 3d). Unlike in clawless, the N-terminal RAX2
extension contains three negative charges, which are in close
proximity to the positively charged Arg87, suggesting a role of
this residue in binding its own N-terminus encircling the
DNA (Fig. 3d). Moreover, FoldX analysis does not indicate
any effect of the p.(Arg87Gln) variant on protein stability or
DNA-binding of the isolated RAX2 homeobox domain. We
therefore speculate on a potential role of Arg87 in
homeodomain–homeodomain interactions at response ele-
ments, which is affected by p.(Arg87Gln), suggestive for a
dominant-negative effect. This role is not necessarily limited
to RAX2/CRX interaction but may even apply to RAX2
homodimer formation.
Bioinformatics findings of the RAX2 CNVs
To assess the underlying mechanisms of the RAX2 CNVs
identified in patients III, V, and VI, bioinformatic analyses
were performed on the breakpoint regions of these deletions.
A summary of the findings is given in Supplementary Table 5,
while the presence of microhomology, repeats, and sequence
motifs is visualized in Supplementary Figure 7. Based on the
results of these extensive analyses, the partial RAX2 deletion
identified in patient III (chr19:3,771,337-3,774,298) may beTa
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p.Ser49Pro p.Pro52Arg
p.Ala113Glyfs*178 HOMEODOMAIN p.Gly137Argp.Arg87Gln
p.Ala156Argfs*131p.Pro140_Gly141dup
RAX2
Helix 3
Arg87
Glu12
Glu70
Helix 3
Helix 2
Helix 1
Ser49
Pro52
Loop 1-2
a
b c
d
CRX
CRX
Glu70
Arg87
RAX2
Helix 3
Helix 2
Positively charged loop in minor groove RAX2:
Clawless:
12
170
hs rax2
pt rax2
mm rax2
bt rax2
qq rax2
xl rxL
dr rx1
dr rx2
hs rax2
pt rax2
mm rax2
bt rax2
qq rax2
xl rxL
dr rx1
dr rx2
hs rax2
pt rax2
mm rax2
bt rax2
qq rax2
xl rxL
dr rx1
dr rx2
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caused either by nonhomologous end-joining (<5-bp micro-
homology) or by a replicative-based repair mechanism. The
absence of an information scar, typical of nonhomologous
end-joining (NHEJ), favors the latter hypothesis. Similarly,
the presence of 4-bp microhomology at the junction of the
complete RAX2 deletion identified in patients V and VI
(chr19:3,765,788-3,772,920) points to NHEJ or a replicative-
based repair mechanism. As the breakpoints of the complete
deletion both overlap with an Alu-repeat, Alu-Alu-mediated
nonallelic homologous recombination (NAHR) cannot be
ruled out. However, these repeats probably do not share
sufficient homology to be used as substrates for NAHR.27 An
assessment of the presence of putative cis-regulatory elements
in the RAX2 CNVs can be found in Supplementary Figure 8.
Deletion g.3771337_3774298del overlaps with the RAX2
promoter and deletion g.3765788_3772920del overlaps with
CRE_3 and CRE_4.
DISCUSSION
We describe five novel RAX2 pathogenic variants, including
both sequence and structural variants, in five apparently
unrelated families segregating nonsyndromic recessive or
sporadic RP. RAX2 had previously only been tentatively
implicated in autosomal dominant CRD and possibly in
AMD.11,12 Our findings therefore firmly support the disease-
causing role of RAX2 in IRD, broadening the range of
phenotypes and inheritance patterns associated with RAX2
pathogenic variants, and providing new insight into IRD
pathogenetic mechanisms.
To date, pathogenic variants in 61 genes, the majority of
which are coding, explain about 60% of ARRP.28 The
remaining cases are assumed to harbor noncoding sequence
or structural variants affecting known IRD genes, missed by
exomic approaches, or to carry pathogenic variants in new
disease genes. Here, we put forward RAX2 as a novel disease
gene for recessively inherited RP. Previously reported RAX2-
associated phenotypes were characterized by progressive
cone–rod type degeneration, while RP is a rod–cone type of
IRD. This may be explained by the fact that different RAX2
pathogenic variants can differentially alter the transactivation
activity of the photoreceptor-specific TFs CRX and NRL. CRX
is a homeobox TF essential for the differentiation of both
cones and rods, and for the maintenance of normal
photoreceptor function through expression modulation of
photoreceptor-specific genes.26 NRL is a TF that is specifically
required for the differentiation of rod photoreceptor cells
through the activation of rod-specific genes.29 RAX2 is able to
bind both to specific TF binding sites and to CRX, which in
turn is associated with NRL, forming a heterotrimeric TF
complex. The latter activates retinal transcription by recruit-
ing other coactivators and components of the basal transcrip-
tion machinery.11 In addition, RAX2, after CRX and NRL, is
one of the top expressed TFs in the adult human retina, which
suggests a major role in the regulation of retinal transcrip-
tion.30 Given the expression and function of NRL in rods, we
hypothesize that the RAX2 variants identified here predomi-
nantly affect the transactivating activity of NRL thus resulting
in a rod–cone instead of a cone–rod phenotype.
The four previously reported RAX2 variants were identified
in patients with CRD or AMD. Segregation was demonstrated
for one variant, c.465_475del, consistent with autosomal
dominant inheritance.12 The heterozygous c.417_422dup
variant identified in a CRD patient has a minor allele
frequency (MAF) of 0.08% in gnomAD and was also present
in the proband’s mother and two siblings said to have normal
vision, challenging the pathogenicity of this heterozygous
variant. For two variants, c.409G>C and c.260G>A, respec-
tively identified in a single CRD and AMD patient, no
segregation analysis was performed.11 These four variants
were reported to cause IRD as dominant alleles that affect
photoreceptor gene transactivation, resulting in a potential
dominant-negative effect. Indeed, two variants were demon-
strated to exhibit increased transactivation activity.11 Here,
biallelic RAX2 variants underlie an RP phenotype, expected to
lead to loss of function, due to the absence of protein
synthesis or the disruption of functional domains. This is
supported by the protein structure modeling of RAX2, where
the recessive p.(Ser49Pro) and p.(Pro52Arg) variants, both
located in the highly conserved homeodomain, are shown to
Fig. 3 Protein alignment with location of RAX2 variants and RAX2 structural analysis. a Amino acid alignment of RAX2 orthologues. Amino acid
sequences deduced from the nucleotide sequences were downloaded from the National Center for Biotechnology Information (NCBI) (https://www.ncbi.
nlm.nih.gov/). The accession numbers of the sequences used in this alignment study are as follows. Homo sapiens: hs_rax2, NM_032753; Pan troglodytes:
pt_rax2, NM_001081487; Macaca mulatta: mm_rax2, XM_001100945; Bos taurus: bt_rax2, NM_182653; Gallus gallus: gg_rax2, AF420601; Xenopus
laevis: xl_rxL, DQ360108; Danio rerio: dr_rx1, AF001907; Danio rerio: dr_rx2, AF001908. The alignment was performed using the MUSCLE algorithm with
default parameters in the Unipro UGENE v1.29.0 software. Gaps required for optimal alignment are indicated by dashes. The color intensity of the amino
acids is according to percentage identity. The highly conserved RAX2 homeodomain is indicated by a black bar. The three RAX2 pathogenic sequence
variants identified in this study are indicated at the amino acid level in black. The four previously reported RAX2 pathogenic variants involved in autosomal
dominant cone-dominated retinal disease are indicated at the amino acid level in gray. b Homology modeling of the RAX2 homeodomain. Structure
superposition of a homology model of the RAX2 homeodomain with six homeodomain crystal structures. The loop between helix 1 and 2, containing Ser49
and Pro52, is structurally conserved. Protein Data Bank (PDB) codes of superposed structures are 3A01_A, 3A01_B, 1FLJ_A, 2H1K_A, 1IG7_A, 5Z2T_C.
cModel for RAX2 and CRX bound to a Ret-1 fragment. In the model, Arg87 of RAX2 interacts with Gln70 of CRX. PDB codes of structure used as template:
3A01_A. d Model with the N-terminal extension of RAX2. In this model, a positively charged region inserts in the minor groove. The RAX2 homeodomain
and its N-terminal domain completely encircle the DNA fragment, and the ring is closed by a Glu12-Arg87 salt bridge. The sequence of the positively
charged region in RAX2 and its counterpart in the clawless template are shown. RAX2 residue Glu12 and clawless site 1 residue (Arg171) are underlined.
Green: negatively charged amino acids. Blue: positively charged amino acids.
VAN DE SOMPELE et al ARTICLE
GENETICS in MEDICINE | Volume 21 | Number 6 | June 2019 1327
greatly disrupt RAX2 folding and/or stability. In contrast,
modeling RAX2 as a RAX2/CRX heterodimer bound to DNA
demonstrates the effect of the dominant p.(Arg87Gln) variant
on homeodomain/DNA higher-order complex formation,
while no effect on protein stability or DNA-binding is
expected. Moreover, no cases of homozygous loss of function
variants in RAX2 are present in the gnomAD database.
Interestingly, the occurrence of both dominant and recessive
IRD phenotypes caused by pathogenic variants in the same
gene has been reported for other retinal TFs. Pathogenic
alleles in CRX are mainly associated with dominant CRD, RP,
and Leber congenital amaurosis (LCA),31,32 but rare biallelic
CRX variants have also been found in LCA.32 Both dominant
and recessive NRL-associated RP could be explained by gain
of function and loss of function of NRL, respectively.33
Finally, a specific missense variant in NR2E3 was found to
lead to autosomal dominant RP by a dominant-negative
effect, while all other NR2E3 variants reported have been
associated with autosomal recessive IRD and enhanced S-cone
syndrome.34
Apart from the novel missense variants in RAX2, both a
partial and complete gene deletion of RAX2 (chr19:3,771,337-
3,774,298 and chr19:3,765,788-3,772,920) were identified,
suggesting a predisposition of this region to structural
variation. The partial deletion spans the start codon of the
gene and is therefore expected to result in complete loss of
function. The current findings highlight the importance of
CNV analysis, which was needed to solve two of the five
families, for an accurate genetic diagnosis in IRD patients. In
addition, one RAX2 frameshift variant, c.335dup p.(Ala113-
Glyfs*178), was identified in two patients of Belgian origin.
Haplotype analysis suggested a common ancestry of this
variant. This variant is assumed to escape NMD and therefore
may give rise to a truncated read-through RAX2 protein with
a disrupted C-terminal region. A dominant-negative effect is
not expected for c.335dup however, because the parents of
both patients I and II do not display a retinal phenotype while
being heterozygous for the variant. RAX2 orthologues contain
a C-terminal OAR domain, the function of which is presumed
to be important for transactivation, protein–protein interac-
tions, or DNA-binding. Although this domain seems to be
weakly conserved in human RAX2, other highly conserved
amino acids are present in the C-terminal region downstream
of c.335dup (Fig. 3a). It has indeed been proposed that other
segments within the C-terminal region of RAX2 orthologues
but outside the OAR domain are involved in transactivation.8
In an earlier study, in vitro luciferase assays demonstrated
that the transactivation activity of RAX2 was able to reach a
peak depending on the amount of RAX2 plasmids used.11 In
addition, a more recent study reported interspecies variation
in the expression of the RAX orthologue in African cichlid
fishes, resulting in variable opsin expression and visual system
diversity.35 This suggests the need for an optimal protein level
for members of the Rax family to function in photoreceptor
gene transactivation. The function of RAX2 and other retinal
TFs therefore appears to be sensitive to alterations in gene
dosage levels, leading to the deregulation of photoreceptor
gene expression, with subsequent photoreceptor degeneration.
The observation that pathogenic variants in the same
transcriptional coactivator gene can result in distinct retinal
phenotypes with different inheritance patterns also reflects the
growing consensus that regulatory networks of retinal gene
expression, defined by precise temporal and spatial patterns,
are so complex that closely located perturbations can result in
different phenotypic manifestations. Further disease modeling
and functional studies will provide more mechanistic insight
into the role of RAX2 loss of function in autosomal recessive
IRD. However, neither rodents nor lagomorphs harbor a
RAX2 orthologue. Xenopus tropicalis on the other hand has a
RAX2 orthologue, rx-l, and has an eye with the same major
cell types as the human eye. This therefore seems an excellent
model organism in which to further study RAX2 loss of
function and its associated phenotypes.36 Interestingly,
morpholino-based knockdown of rx-l in Xenopus appeared
to impair late retinogenesis and reduce photoreceptor-specific
gene expression.8 This is in line with the phenotype observed
in human IRD due to biallelic RAX2 variants.
To conclude, we found biallelic pathogenic variants in
RAX2 to be associated with ARRP, revealing RAX2 as a novel
gene for recessively inherited rod-dominated retinal diseases.
The identification of RAX2 biallelic pathogenic variants in five
families of European origin indicates that this gene may
underlie a nonnegligible fraction of ARRP cases of other
populations that still lack a molecular diagnosis. The RAX2
mutational spectrum was broadened from sequence to
structural variants. Moreover, the identification of pathogenic
structural variants in RAX2 stresses the importance of CNV
assessment in exome and genome sequencing data in IRD.
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